Discover how AI is revolutionizing RNA drug development in a new article published in Engineering. Learn about the potential ...

In the realm of modern medicine, RNA-based therapies have emerged as a promising avenue, with significant advancements in metabolic diseases, oncology, and preventive vaccines. A recent article ...

In this article, we examine ongoing challenges shaping target-based drug discovery and highlight how new technologies and ...

TOKYO--(BUSINESS WIRE)--Elix, Inc. (CEO: Shinya Yuki / Headquarters: Tokyo; hereinafter “Elix”) is pleased to announce that its AI drug discovery platform, Elix ...

KAIST (President Kwang Hyung Lee) announced on the 10th that a research team led by Professor Woo Youn Kim in the Department of Chemistry has developed an AI model named BInD (Bond and ...

Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, with a focus on obesity, today ...

Genesis’ proprietary foundation model – Pearl – outperforms frontier models, including AlphaFold 3, on key benchmarks that predict utility in real-world drug discovery Pearl’s performance improved ...

An illustration of an algorithm predicting a protein structure, with digitized blocks on the left becoming ribbons on the right. An illustration of the RoseTTAFold software predicting a protein ...